Granulocytes and monocytes/macrophages from patients suffering from chronic granulomatous disease (CGD) are ineffective in killing specific kinds of phagocytized bacteria, e.g., Staphylococcus aureus, due to decreased or lacking ability to produce reactive oxygen intermediates. Commonly used antibiotics like flucloxacillin are of limited therapeutic value, because the staphylococci are protected against their action in the interior of phagocytes. However, encapsulation of flucloxacillin into liposomes could enable its entrance into the interior of neutrophils from two CGD patients to kill phagocytized bacteria there. The effect ofrifampicin against intracellular staphylococci could be similarly enhanced by liposome encapsulation. Dose-response relations and kinetics of killing of intracellular bacteria by antibiotics in the free and encapsulated form were studied under different conditions using J 774 mouse macrophages, because phagocytes from CGD patients are not available in great amounts. Preincubation of phagocytes with either antibiotic in liposomes subsequently endowed the cells with a strongly enhanced ability to kill phagocytized bacteria. Our data show that a drug which normally will not reach a phagosome can be delivered to this intracellular compartment by a liposome.
Introduction
Chronic granulomatous disease (CGD)' is characterized by se- vere infections with catalase positive bacteria (e.g., Staphylococcus aureus) like pyoderma, lymphadenitis with granuloma formation, abscesses in lung, liver, spleen, or bone marrow, or severe mycotic infections, etc. The clinical features of this disease are the result of a total lack of or a decreased ability of patients' phagocytes to produce microbicidal reactive oxygen 1. Abbreviations used in this paper: CGD, chronic granulomatous disease; MO, macrophages. intermediates. This inability is due to a variety of inherited primary biochemical disorders (1-6). Most frequently the xlinked form is associated with a deficiency of nonmitochondrial cytochrome b5_8 activity whereas the autosomal form is linked to a deficiency in cytosolic factor functions (7-9).
The prognosis of CGD is very poor for untreated patients, but it can be highly improved by the therapeutic and prophylactic use of antibiotics that are able to penetrate into the interior ofphagocytes to kill phagocytized bacteria there. However, the number of antibiotics displaying this penetration of cell membranes is limited (10) .
The liposomes of the composition used here are preferentially taken up by neutrophils, monocytes, and macrophages (M+). They are able to carry enclosed agents into the interior of these phagocytes (1 1, 12). The merits ofchemotherapy ofintracellular infections in phagocytes by liposome enclosed agents has been demonstrated by several investigators (13) (14) (15) (16) (17) (18) .
The data presented suggest that antibiotics (and perhaps antimycotics) that cannot penetrate cell membranes could perhaps become suitable for therapy of CGD by encapsulation into liposomes. Furthermore, the effectiveness of rifampicin which is already used in CGD could be enhanced by this encapsulation.
Methods
RPMI 1640 medium was supplemented with 5% pooled AB serum (both from Gibco Laboratories, Grand Island, NY, hereafter referred to as complete medium). Percoll was purchased from Pharmacia Fine Chemicals, Uppsala, Sweden, and diluted to appropriate concentrations in NaCl (0.15 M final concentration). Distilled water and 1.8% (wt/vol) NaCl solution were used to lyse erythrocytes contaminating suspensions and aliquots from the supernatants resulting from the ultracentrifugation step were tested for their minimal inhibitory concentration with respect to multiplication of staphylococci. The amount of enclosed antibiotic could be calculated from the minimal inhibitory concentration of the liposome fraction and from the stock solution with known concentrations of the antibiotic under consideration. The results could be further confirmed by a balance test (calculated amounts in the liposome fractions plus calculated amounts in the supernatant were always approximately equal to the total amounts originally used). In the case of rifampicin a further confirmation could be achieved by optical density measurements at 475 nm. The results of experiments obtained from rifampicin liposomes prepared in our lab were always identical to those obtained with rifampicin liposomes that were kindly provided by Ciba-Geigy.
Stability ofthe liposomes was tested according to the determination ofthe amounts ofentrapped antibiotics. Afterpreparation and centrifugation aliquots of the liposomal pellet were diluted 1:100 in complete medium and incubated for different time intervals at different temperatures (Fig. 1) . The samples were then spun again and the contents ofthe respective antibiotics were evaluated in the pellet and the supernatant. Both kinds of liposomes were stable at 370C over the experimental time period (7 h) in the medium used for cell culture (Fig. 1) .
Preparation of monolayers ofphagocytes. PMN were obtained by Percoll gradient centrifugation from heparinized blood (10 IU/ml). This gradient was layered in 15-ml plastic tubes (Falcon Labware, Becton Dickinson & Co., Oxnard, CA) in two steps of 4-ml Percoll solutions: 69% (density = 1.085) and 55% (density = 1.069). The tubes were spun at 350 g for 20 min. PMN migrated between the two layers whereas mononuclear cells remained on the top of the gradient. The cell fractions were harvested. Remaining erythrocytes were removed by hypotonic lysis using equal volumes of distilled water and 1.8% NaCl solution.
After an additional washing step in complete medium the PMN were counted and adjusted to appropriate final concentrations. After washing, the mononuclear cells were layered on a second continuous Percoll gradient according to 
Effects on staphylococci in CGD neutrophils
The ability of this liposome-encapsulated flucloacillin to kill intracellular bacteria was tested as follows: PMN lacking any ability to produce reactive oxygen intermediates from CGD patients were incubated with staphylococci to enable phagocytosis of these bacteria. After removal of most remaining extracellular bacteria by washing, the PMN were incubated with flucloxacillin either enclosed in liposomes or in the free form. Plate counting revealed that a significant reduction of viable bacteria was achieved by liposome-encapsulated flucloxacillin only (Fig. 2 A) : the number ofbacteria surviving intracellularly was -20% ofthe respective number resulting from incubation with free flucloxacillin or with medium only. Similar results were obtained using monocytes instead of PMN (Fig. 2 B) . Similar experiments were performed using 10 mg/ml rifampicin instead of flucloxacillin. The killing of intracellular staphylococci in CGD PMN was enhanced significantly by encapsulation of rifampicin into liposomes, but the amount of improvement over the free form was less than that of flucloxacillin (it was -40%, Fig. 2 C, vs. 80%, Fig. 2 A) . This smaller encapsulation effect is probably due to the fact that free rifampicin can penetrate membranes of cells while flucloxacillin can not.
As a control, free staphylococci were incubated with free vs. enclosed antibiotics (Fig. 1 D) . As expected, free antibiotics were always significantly more effective in reducing the number of extracellular bacteria. In addition, empty liposomes in concentrations used here had no effect on survival or on multiplication offree orphagocytized staphylococci (Fig. 5) . Furthermore, the presence of empty liposomes neither decreased the number ofphagocytized bacteria nor enhanced the weak spontaneous killing in J 774 mouse macrophages by activation.
Dose response relations and kinetics ofkilling ofstaphylococci in J 774 phagocytes These cells were used for more detailed studies ofdose response relations and kinetics of bacterial killing because cells from CGD patients are not available in great amounts. The better effect of antibiotics in liposomes on the killing ofphagocytized bacteria over a wide range ofconcentrations is demonstrated in Fig. 3, A and C netics of killing of intracellular bacteria (Fig. 4 , A and C). Rifampicin (A) and flucloxacillin (C) in concentrations which in the free form still allow multiplication of the staphylococci became more bactenostatic or even bactericidal by encapsulation. The J 774 macrophages could be endowed with strongly enhanced abilities to kill staphylococci by preincubation with relatively low concentrations of encapsulated antibiotics (Fig.   3, B and D) . Much higher concentrations ofthe free forms were needed for similar effects. Again, this result could be confirmed by kinetic studies (Fig. 4, B and D) . In contrast to free rifampicin, preincubation of J 774 cells with 100 ng/ml of the encapsulated form had a bacteriostatic effect (Fig. 4 B) . However, preincubation with 1 gg/ml flucloxacillin in liposomes could only decrease but could not stop bacterial multiplication (D).
Two similar experiments preincubating phagocytes with antibiotics could be carried out with neutrophils from a CGD patient. CFU numbers resulting from 2-h preincubation with 0.1 mg/ml rifampicin or 1 mg/ml flucloxacillin in liposomes were -50% or 40%, respectively, as compared to preincubation with the free form. Thus, the results using J 774 macrophages are transferable in principle to CGD phagocytes.
To further exclude the possibility that these results were due to disturbance of phagocytosis caused by liposomes or antibiotics, we incubated pretreated J 774 cells with yeast cells of the species Candida albicans. Phagocytosis of this yeast was not altered by any of the pretreatments used as determined by cell staining according to Pappenheim and microscopical counting of 200 cells for each condition.
To test whether liposomes suppress intracellular bacterial growth by delivery of antibiotics or by providing an adjuvant effect, we incubated cells containing bacteria with free antibiotics and empty liposomes (Fig. 5) . Since only encapsulation of antibiotics, but not addition ofempty liposomes, increased killing of intracellular bacteria, we conclude that liposomes do not provide an adjuvant effect. The statistical significance and the range of scatter of the results for all test conditions are given in Table I .
Discussion
PMN from CGD patients show normal phagocytosis ofstaphylococci, but are ineffective in killing them. Flucloxacillin is not able to penetrate cell membranes ofPMN or monocytes. Therefore, its therapeutic effect in CGD is very limited because common pathogenic bacteria like Staphylococcus aureus are protected intracellularly against its action. Liposomes could enable entrance of the antibiotic into the interior of phagocytes from two CGD patients to kill phagocytized staphylococci id composition (26 
